Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C231/00—Preparation of carboxylic acid amides
  • C07C231/22—Separation; Purification; Stabilisation; Use of additives

Definitions

• This invention refers to a new process for the crystallization of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl) ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide (I), using a linear or branched (C5-C6) alcohol or their mixtures.
• the compound (I) is best known as Iopamidol, which is one of the world top compounds in the field of non-ionic X-ray contrast media.
• EP-A-0 747 344 discloses the use of propanol or isopropanol as crystallization solvent to overcome the problem of the formation of pasty products during the crystallization.
• Iopamidol can be easily crystallized from the homologous (C5-C6) alcoholic solvents, with industrially acceptable yields and giving a product which meets the pharmacopoeia standards.
• the preferred solvents are selected from the following groups: hexanol, pentanol, 2-pentanol and 3-pentanol mixture, and iso-pentanol.
• the improvement of this invention consists in the use of solvents able to give azeotropes with water forming two separate layers; the lower level has a minimal removable solvent content, while the upper one can be recycled.
• the solvents of this invention are those with a higher water percentage in the upper layer and form separate layers, except for n-BuOH and iso-BuOH.
• the recycled upper layer has a very low residual water content with respect to that of n-BuOH and iso-BuOH.
• the residual water content present in the upper layer of the solvents of this invention is lower than 15% (w/w) and so Iopamidol can be crystallized, if necessary, without anhydrifying them.
• the upper layer can be cooled and used it for washing the wet filtration cake. This procedure is absolutely new and is a great improvement from the industrial point of view.
• the recovery of the solvent is easy and the upper layer can be directly used in the process of this invention without anhydrifying it.
• the industrial process for the recovery of the solvent does not need elaborate systems or processes such as pervaporation or the simple addition of a little amount of a third solvent to the binary azeotropic mixture, -for example toluene or cyclohexane, able to form a ternary azeotrope with water.
• a crude aqueous solution of Iopamidol 5-25% (w/w) is concentrated under vacuum at a pressure of 3-12 mmHg (400-1600 Pa) or atmospheric pressure, at a temperature comprised between 50 and 100°C to have a water residual content comprised between 15-35% (w/w). Then the mixture is heated or cooled, depending on the case, and the crystallization solvent is added at a temperature comprised between 85-95°C, maintaining this temperature during the addition.
• the amount of the solvent to be used is from 0.8 to 6 times (w/w) with respect to the amount of theoretical Iopamidol.
• the solvent amount is from 0.8 to 4.5 times (w/w) with respect to the amount of theoretical Iopamidol.
• the water content is not considered, because water-saturated solvents can be used.
• the mixture is azeotropic distilled, recycling the upper layer until the two layers are dissolved.
• the distillation can be carried out to have a water residual content from 4 to 10% in the floating liquid.
• the solid can precipitate during this step, eventually by germination. In some cases it is possible to add the solvent in two or three consecutive portions.
• the distillation can be stopped and the mixture is cooled at the temperature from 60 to 80°C and then germinate.
• the distillation can be resumed until the water final content in the floating liquid is reached.
• the solid is filtered, washed with dry solvents or with a quantity of the wet recycled solvent from the upper layer of the distilled azeotropic mixture.
• the amount of the solvent is from 0.4 to 2 times (w/w) with respect to the amount of theoretical Iopamidol, preferably from 0.4 to 1 time.
• the wet product is dried under a pressure comprised between 1 - 10 mmHg (133.3-1333 Pa), preferably between 3 - 7 mmHg (400-933.2 Pa) at a temperature comprised between 75°C and 95°C during at least 16 hours.
• the product is very stable, and decomposes at about 300°C without melting (see for example Merck Index 12th edition).
• the residual content of the crystallization solvent is lower than 60 ppm.
• the following examples serve to illustrate this invention and are not, in any way, to be considered as a limitation thereof.
• the water content in the azeotrope and in the final product was determined by the Karl-Fisher method, while the content of the solvent in the final product was determined by gas-chromatography.
• the mixture is stirred at this temperature until the product terminates its crystallization (about 1 hour). Then the mixture is refluxed again recycling the upper layer of the azeotrope mixture distilled, to reach a 7.2% residual content of water in the floating liquid. The mixture is refluxed for 60 min., then cooled to 25°C and kept at this temperature for 3 hours. The product is filtered, washed with two portions of 50 kg of the upper phase of the azeotrope.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Applications Claiming Priority (1)

Publications (2)

Family

ID=11004529

Family Applications (1)

Country Status (11)

Families Citing this family (4)

Family Cites Families (5)

• 1997
  • 1997-02-11 WO PCT/IB1997/000106 patent/WO1998034908A1/en not_active Ceased
  • 1997-02-11 ES ES97901229T patent/ES2141691T3/es not_active Expired - Lifetime
  • 1997-02-11 AU AU14553/97A patent/AU1455397A/en not_active Abandoned
  • 1997-02-11 DE DE0966428T patent/DE966428T1/de active Pending
  • 1997-02-11 CZ CZ0282599A patent/CZ299420B6/cs not_active IP Right Cessation
  • 1997-02-11 JP JP53403098A patent/JP4080545B2/ja not_active Expired - Lifetime
  • 1997-02-11 KR KR1019997007191A patent/KR100758741B1/ko not_active Expired - Lifetime
  • 1997-02-11 DE DE69717156T patent/DE69717156T2/de not_active Expired - Lifetime
  • 1997-02-11 EP EP97901229A patent/EP0966428B1/en not_active Expired - Lifetime
• 1998
  • 1998-02-09 US US09/020,424 patent/US6037494A/en not_active Expired - Fee Related
  • 1998-02-10 ZA ZA981070A patent/ZA981070B/xx unknown
• 1999
  • 1999-08-10 NO NO19993851A patent/NO325570B1/no not_active IP Right Cessation

Also Published As

Similar Documents

Legal Events